- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cancer and Blood Specialists of NOVA Has Joined the American Oncology Network
American Oncology Network, LLC (AON) is pleased to announce that Cancer and Blood Specialists of NOVA, a leading community oncology and hematology practice serving Northern Virginia, has joined AON.
Fort Myers, Fla., May 4, 2020—American Oncology Network, LLC (AON) is pleased to announce that Cancer and Blood Specialists of NOVA, a leading community oncology and hematology practice serving Northern Virginia, has joined AON, effective May 1, 2020.
Cancer and Blood Specialists of NOVA has been providing comprehensive, state-of-the-art treatment for patients diagnosed with cancer and blood disorders at its clinic in the Washington D.C. Metropolitan area since 1987. The practice was founded by Medical Oncologist and Hematologist Dr. Masoom Kandahari. Dr. Kandahari is currently joined by Medical Oncologist and Hematologist Dr. Farn Chan and a nurse practitioner.
“We are excited to have Drs. Kandahari and Chan join AON,” said AON CEO Brad Prechtl, MBA. “Cancer and Blood Specialists of NOVA will continue to offer the highest level of cancer care with enhanced services such as home delivery for oral oncolytic medications and centralized laboratory and pathology services for quicker results.”
“This partnership with AON and the Cancer and Blood Specialists of NOVA will help drive change in community cancer care with access to advanced technologies and the latest treatment options for Virginia patients,” said AON Board Member & Chairman Dr. Stephen Orman.
Read the full press release here.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
